Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors
Recruiting
- Conditions
- cancermalignancies10027655
- Registration Number
- NL-OMON53128
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1500
Inclusion Criteria
Patients using a (currently approved or new) targeted anti-cancer agent for
treatment of cancer
Patients from whom it is possible to collect blood samples
Informed consent is given
Exclusion Criteria
nvt
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>•Pharmacokinetics</p><br>
- Secondary Outcome Measures
Name Time Method <p>•Treatment outcome (response, suboptimal response, treatment failure)<br /><br>•Toxicity (graded on basis of the National Cancer Institute Common Toxicity<br /><br>Terminology grading Criteria for adverse events (CTCAE)<br /><br>•Genotype of drug metabolising enzymes and drug transporters<br /><br>•Mutations and/or alterations in drug targets<br /><br>•Drug-drug interactions</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets are most responsive to therapeutic drug monitoring in tyrosine kinase inhibitor-treated cancer patients?
How does TDM-guided dosing of tyrosine kinase inhibitors improve outcomes compared to standard-of-care regimens in malignancies?
Which biomarkers correlate with optimal plasma concentrations of tyrosine kinase inhibitors in the NIB cohort study?
What adverse events are associated with tyrosine kinase inhibitor therapy in the NIB cohort, and how does TDM mitigate them?
How do combination therapies involving tyrosine kinase inhibitors and immune checkpoint inhibitors perform under TDM in cancer?